Clopidogrel with aspirin doesn't prevent more small strokes, may increase risk of bleeding, death

American Stroke Association late-breaking science - abstract LB9-4504

2012-02-06

(Press-News.org) The anti-blood clot regimen that adds the drug clopidogrel (Plavix) to aspirin treatment is unlikely to prevent recurrent strokes and may increase the risk of bleeding and death in patients with subcortical stroke according to late-breaking research presented at the American Stroke Association's International Stroke Conference 2012.

Because of these preliminary results, researchers ended the anti-clotting part of the Secondary Prevention of Small Subcortical Strokes Trial (SPS3) in August 2011. The part of the study that examines the effect of high blood pressure treatments will continue. The SPS3 trial is the first large-scale study of patients with subcortical strokes, which occur when small blood vessels deep in the middle of the brain are blocked, damaging small areas of brain tissue. This type of stroke affects about 150,000 Americans each year, and is the most common cause of vascular dementia according to Oscar Benavente, M.D., lead author of the study and a professor of neurology at Canada's University of British Columbia in Vancouver, British Columbia.

American Heart Association/American Stroke Association guidelines for preventing recurrent strokes recommend anti-clotting medications like aspirin, the customary treatment, or other clot preventives like clopidogrel, but not the combination of aspirin plus clopidogrel.

Treatments have not been compared in patients with subcortical strokes specifically.

In the United States, stroke is the No. 4 killer and a leading cause of disability among adults.

Beginning in March 2003, the SPS3 study included 3,020 patients at 81 sites in the United States, Canada, Spain, Mexico and South America. Stroke patients were randomly assigned within 180 days of symptom onset to receive aspirin and clopidogrel or aspirin plus placebo daily. Neither researchers nor patients knew who received placebo or the study drug.

Preliminary findings showed that the risk of bleeding nearly doubled among patients on the clopidogrel/aspirin combination, compared to those on aspirin and placebo: Aspirin plus placebo had a 1.1 percent of bleeding risk per year and aspirin plus clopidogrel a 2.1 percent bleeding risk per year – largely from major bleeds somewhere other than in the brain.

Similarly, the annual risk of death was greater with the combined therapy: Aspirin plus placebo had a 1.4 percent risk of death and aspirin plus clopidogrel had a 2.1 percent risk of death.

There was no difference in stroke recurrence in both treatment arms.

"These interim results do not support the use of combination clopidogrel plus aspirin for secondary stroke prevention in patients with small subcortical strokes," the researchers said.

### Co-investigator is Robert G. Hart, M.D. Author disclosures are on the abstract.

The National Institutes of Health, National Institute of Neurological Diseases and Stroke, funded the study.

Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing science content. Revenues from pharmaceutical and device corporations are available at http://www.heart.org/corporatefunding.

NR12-1026 (ISC 2012/Benavente)

(Note: Actual presentation is 12:12 p.m. CT Friday, Feb. 3, 2012.)

Additional resources: All downloadable video/audio interviews, B-roll, animation and images related to this news release are located on the right column of the release link located at http://newsroom.heart.org/pr/aha/_prv-clopidogrel-with-aspirin-doesn-228204.aspx General ISC video and ISC photos available at http://www.newsroom.heart.org/ISC12-Video or http://www.newsroom.heart.org/ISC12-Photos. Follow news from ASA International Stroke Conference 2012 via Twitter: http://twitter.com/#!/heartnews. Follow #ASANews12.

ELSE PRESS RELEASES FROM THIS DATE:

New drug doesn't improve disability among stroke patients

2012-02-06

A new drug that showed promise in animal studies and an early clinical trial didn't improve disability among stroke patients, according to late-breaking research presented at the American Stroke Association's International Stroke Conference 2012. After a stroke and other types of brain damage, the brain naturally produces more granulocyte colony stimulating factor (G-CSF). The protein can prevent further cell injury by protecting nerve cells and boosting blood vessel growth. The new drug, AX200, is a manufactured form of G-CSF. Ninety days after treatment, patients ...

Vitamin D deficiency in geriatric patients

2012-02-06

The great majority of geriatric patients in a German rehabilitation hospital were found to have vitamin D deficiency. Stefan Schilling presents his study results in this week's issue of Deutsches Ärzteblatt International (Dtsch Arztebl Int 2012; 109[3]: 33-8). In order to establish the vitamin D status in geriatric patients in Germany, the researchers measured 25-OH vitamin D in 1578 patients in the geriatric rehabilitation hospital in Trier after they had been examined on admission. Insufficiently high concentrations were found in 89% of patients, and 67% had severe ...

Rare mutations may help explain aneurysm in high-risk families

2012-02-06

An innovative approach to genome screening has provided clues about rare mutations that may make people susceptible to brain aneurysms, predisposing them to brain bleeds, according to preliminary late-breaking research presented at the American Stroke Association's International Stroke Conference 2012. For the first time, scientists applied a process called whole exome sequencing to seek gene mutations in families in which multiple relatives have intracranial aneurysms, a condition in which weakened, ballooned-out areas in arteries of the brain can rupture and cause a ...

Warfarin and aspirin are similar in heart failure treatment

2012-02-06

In the largest and longest head-to-head comparison of two anti-clotting medications, warfarin and aspirin were similar in preventing deaths and strokes in heart failure patients with normal heart rhythm, according to late-breaking research presented at the American Stroke Association's International Stroke Conference 2012. "Although there was a warfarin benefit for patients treated for four or more years, overall, warfarin and aspirin were similar," said Shunichi Homma, M.D., lead author of the study and the Margaret Milliken Hatch Professor of Medicine at Columbia University ...

Scientists chart high-precision map of Milky Way's magnetic fields

2012-02-06

Scientists at the Naval Research Laboratory (NRL) are part of an international team that has pooled their radio observations into a database, producing the highest precision map to date of the magnetic field within our own Milky Way galaxy. The team, led by the Max Planck Institute for Astrophysics (MPA), used the database they created and were able to apply information theory techniques to produce the map, explains NRL's Dr. Tracy Clarke, a member of the research team. "The key to applying these new techniques is that this project brings together over 30 researchers ...

A new study shows how to boost the power of pain relief, without drugs

2012-02-06

Placebos reduce pain by creating an expectation of relief. Distraction—say, doing a puzzle—relieves it by keeping the brain busy. But do they use the same brain processes? Neuromaging suggests they do. When applying a placebo, scientists see activity in the dorsolateral prefrontal cortex. That's the part of the brain that controls high-level cognitive functions like working memory and attention—which is what you use to do that distracting puzzle. Now a new study challenges the theory that the placebo effect is a high-level cognitive function. The authors—Jason T. Buhle, ...

Schooling protects fleeing children from disease

2012-02-06

Refugee children have scant access to medical care and are particularly vulnerable to disease. Fresh research results from the University of Copenhagen show that just a few hours of schooling a week may have a pronounced positive impact on their health not only in childhood but later in life when they achieve adulthood. "There is an unambiguous link between health and schooling among refugee groups as they flee," says external Associate Professor Tania Dræbel, PhD from the Department of Public Health, University of Copenhagen, where she works as an expert in health among ...

The complex relationship between memory and silence

2012-02-06

People who suffer a traumatic experience often don't talk about it, and many forget it over time. But not talking about something doesn't always mean you'll forget it; if you try to force yourself not to think about white bears, soon you'll be imagining polar bears doing the polka. A group of psychological scientists explore the relationship between silence and memories in a new paper published in Perspectives on Psychological Science, a journal of the Association for Psychological Science. "There's this idea, with silence, that if we don't talk about something, it starts ...

UC San Diego Moores Cancer Center offers new hope for deadly brain tumor

2012-02-06

Jim Black is fighting the meanest, most aggressive, most common kind of brain tumor in the United States: recurrent glioblastoma multiforme (GBM). In the United States, each year, approximately 10,000 patients are affected by GBM. Now, a novel investigational device – available only at clinical trial sites – is offering new hope to these patients. The non-invasive procedure – called Tumor Treating Fields (TTF) – is delivered using a portable device – called the NovoTTF-100A System made by Novocure. The TTF procedure uses alternating electrical fields to disrupt the ...

Largest Bin Database Service Released

2012-02-06

BinDataSet, an BIN database service provider, has released the largest BIN database on the Internet. The database contains over 350,000 records. What is BIN? BIN stands for Bank Identification Numbers. It is a database that contains credit and debit card numbers. On top of that, the database also provides additional information such as Country, Brand, and Bank. Most BIN databases provide only card type and brand. BinDataSet ensures that more fields are available for higher accuracy. Why is there a need for BIN databases? The Internet is growing at an amazing ...

Clopidogrel with aspirin doesn't prevent more small strokes, may increase risk of bleeding, death

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: